 NEW HAVEN, Conn.-- BUSINESS WIRE --Rallybio Corporation Nasdaq: RLYB, a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced its participation in the following upcoming investor conferences: 